Health ❯ Healthcare ❯ Drug Safety

Adverse Effects

Clinical Study Results Treatment-Related Adverse Effects Patient Safety Clinical Guidelines Warnings and Precautions Eye Health Tolerability Studies Osimertinib Toxicity Guillain-Barré Syndrome Osimertinib Treatment Tolerability Ocular Toxicity Tolerability Treatment-Related AEs Gastrointestinal Symptoms Mifepristone Complications Tramadol Side Effects Anemia Clinical Outcomes Pertuzumab-dpzb Adverse Effects Medication Tolerance Cardiovascular Risks Trial Outcomes Neurological Problems

AstraZeneca’s LATIFY Phase 3 Finds No Survival Benefit for Ceralasertib Plus Imfinzi in Pre-Treated NSCLC

The study tested an ATR inhibitor with Imfinzi in patients whose disease progressed after immunotherapy plus platinum chemotherapy.

Lilly’s Daily Obesity Pill Sustains Weight Loss After Switch From Wegovy or Zepbound

Nektar’s Alopecia Drug Misses Phase 2b Goal as Company Cites Ineligible Patients, Plans Phase 3

FDA Grants Full Approval to Jaypirca for Relapsed CLL/SLL After Covalent BTK Therapy

FDA Approves Poherdy as First Interchangeable Biosimilar to Perjeta for HER2-Positive Breast Cancer

FDA Reapproves GSK’s Blenrep for Multiple Myeloma in Narrow Combination Use

WCLC 2025: Combination Approaches Redraw EGFR-Mutant NSCLC Care

Amgen Advances Monthly Obesity Drug to Phase 3 After 20% Weight Loss in Mid-Stage Trial